Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.

PMID:
29631810
2.

Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases.

Nagano H, Obi S, Hatano E, Kaneko S, Kanai F, Omata M, Tsuji A, Itamoto T, Yamamoto K, Tanaka M, Kubo S, Hirata K, Nakamura H, Tomimaru Y, Yamanaka T, Kojima S, Monden M.

Hepatol Res. 2018 Aug;48(9):717-726. doi: 10.1111/hepr.13067. Epub 2018 Mar 12.

PMID:
29377364
3.

Leucine-rich α2-glycoprotein overexpression in the brain contributes to memory impairment.

Akiba C, Nakajima M, Miyajima M, Ogino I, Miura M, Inoue R, Nakamura E, Kanai F, Tada N, Kunichika M, Yoshida M, Nishimura K, Kondo A, Sugano H, Arai H.

Neurobiol Aging. 2017 Dec;60:11-19. doi: 10.1016/j.neurobiolaging.2017.08.014. Epub 2017 Aug 24.

4.

A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Nagai K, Nakagawa T, Sugawara T, Hanaoka H, Kanai F, Yokosuka O.

Hepatology. 2018 Feb;67(2):575-585. doi: 10.1002/hep.29403. Epub 2017 Dec 23.

PMID:
28746788
5.

Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma.

Ogasawara S, Chiba T, Motoyama T, Kanogawa N, Saito T, Shinozaki Y, Suzuki E, Ooka Y, Tawada A, Kato H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O.

PLoS One. 2016 Sep 20;11(9):e0163119. doi: 10.1371/journal.pone.0163119. eCollection 2016.

6.

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2016 Apr;34(2):255-60. doi: 10.1007/s10637-016-0323-1. Epub 2016 Jan 14.

PMID:
26769245
7.

Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2015 Dec;33(6):1257-62. doi: 10.1007/s10637-015-0292-9. Epub 2015 Oct 14.

PMID:
26462681
8.

Intensity-Based Assessment of Microbubble-Enhanced Ultrasonography: Phase-Related Diagnostic Ability for Cellular Differentiation of Hepatocellular Carcinoma.

Kondo T, Maruyama H, Kiyono S, Sekimoto T, Shimada T, Takahashi M, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Chiba T, Kanai F, Yokosuka O.

Ultrasound Med Biol. 2015 Dec;41(12):3079-87. doi: 10.1016/j.ultrasmedbio.2015.07.033. Epub 2015 Sep 12.

PMID:
26371403
9.

Aberrant differentiation of Tsc2-deficient teratomas associated with activation of the mTORC1-TFE3 pathway.

Kawano H, Ito Y, Kanai F, Nakamura E, Tada N, Takai S, Horie S, Kobayashi T, Hino O.

Oncol Rep. 2015 Nov;34(5):2251-8. doi: 10.3892/or.2015.4254. Epub 2015 Sep 8.

10.

Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Invest New Drugs. 2015 Jun;33(3):729-39. doi: 10.1007/s10637-015-0237-3. Epub 2015 Apr 12.

PMID:
25861764
11.

Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study.

Sato T, Kondo F, Ebara M, Sugiura N, Okabe S, Sunaga M, Yoshikawa M, Suzuki E, Ogasawara S, Shinozaki Y, Ooka Y, Chiba T, Kanai F, Kishimoto T, Nakatani Y, Fukusato T, Yokosuka O.

Hepatol Int. 2015 Apr;9(2):330-6. doi: 10.1007/s12072-015-9620-6. Epub 2015 Mar 3.

12.

Establishment of Tsc2‑deficient rat embryonic stem cells.

Ito Y, Kawano H, Kanai F, Nakamura E, Tada N, Takai S, Horie S, Arai H, Kobayashi T, Hino O.

Int J Oncol. 2015 May;46(5):1944-52. doi: 10.3892/ijo.2015.2913. Epub 2015 Mar 3.

PMID:
25738543
13.

Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.

Tawada A, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Ogasawara S, Suzuki E, Kanai F, Yoshikawa M, Yokosuka O.

Anticancer Res. 2015 Jan;35(1):549-54.

PMID:
25550601
14.

Partial splenic embolization with transarterial chemoembolization in patients with hepatocellular carcinoma accompanied by thrombocytopenia.

Ooka Y, Chiba T, Ogasawara S, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O.

Biomed Res Int. 2014;2014:960628. doi: 10.1155/2014/960628. Epub 2014 Sep 15.

15.

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O.

Oncology. 2014;87(6):330-41. doi: 10.1159/000365993. Epub 2014 Sep 6.

PMID:
25227534
16.

Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma.

Tawada A, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Saito T, Ogasawara S, Suzuki E, Maruyama H, Kanai F, Yoshikawa M, Yokosuka O.

Anticancer Res. 2014 Aug;34(8):4231-7.

PMID:
25075052
17.

A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka AO.

Invest New Drugs. 2014 Aug;32(4):762-8. doi: 10.1007/s10637-014-0097-2. Epub 2014 Apr 16.

PMID:
24737402
18.

A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.

Ooka Y, Chiba T, Ogasawara S, Arai K, Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O.

Invest New Drugs. 2014 Aug;32(4):723-8. doi: 10.1007/s10637-014-0077-6. Epub 2014 Mar 7.

PMID:
24599799
19.

Circulating cancer stem cells: a novel prognostic predictor of hepatocellular carcinoma.

Chiba T, Kanai F, Iwama A, Yokosuka O.

Hepatobiliary Surg Nutr. 2013 Feb;2(1):4-6. doi: 10.3978/j.issn.2304-3881.2012.09.02. No abstract available.

20.

An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

Kanai F, Obi S, Fujiyama S, Shiina S, Tamai H, Mochizuki H, Koike Y, Imamura J, Yamaguchi T, Saida I, Yokosuka O, Omata M.

Hepatol Int. 2014 Jan;8(1):94-103. doi: 10.1007/s12072-013-9459-7. Epub 2013 Jul 25.

PMID:
26202410
21.

Successful non-surgical treatment of ruptured pyogenic liver abscess.

Motoyama T, Ogasawara S, Chiba T, Suzuki E, Yokota H, Haga Y, Kanogawa N, Saito T, Ooka Y, Tawada A, Kanai F, Yokosuka O.

Intern Med. 2013;52(23):2619-22.

22.

Natural history of postvascular-phase iso-enhanced lesions on the sonogram in chronic liver diseases.

Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Chiba T, Kanai F, Yokosuka O, Yamaguchi T.

J Gastroenterol Hepatol. 2014 Jan;29(1):165-72. doi: 10.1111/jgh.12449.

PMID:
24224484
23.

Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan.

Shimada T, Maruyama H, Kondo T, Sekimoto T, Takahashi M, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Chiba T, Kanai F, Okabe S, Yoshikawa M, Yokosuka O.

Hepatol Int. 2013 Oct;7(4):1030-9. doi: 10.1007/s12072-013-9470-z. Epub 2013 Aug 28.

PMID:
26202032
24.

Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.

Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Tada M, Kanai F, Takiguchi Y, Iwama A, Yokosuka O.

PLoS One. 2013 Jul 29;8(7):e70010. doi: 10.1371/journal.pone.0070010. Print 2013.

25.

A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.

Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y.

Eur J Cancer. 2013 Sep;49(13):2832-40. doi: 10.1016/j.ejca.2013.05.011. Epub 2013 Jun 10.

PMID:
23764238
26.

Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Ogasawara S, Kanai F, Ooka Y, Motoyama T, Suzuki E, Tawada A, Chiba T, Yokosuka O.

Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12.

PMID:
26201804
27.

Successful resection of intracranial metastasis of hepatocellular carcinoma.

Okimoto K, Ogasawara S, Chiba T, Kanai F, Yokota H, Motoyama T, Suzuki E, Ooka Y, Tawada A, Iwadate Y, Saeki N, Yokosuka O.

Case Rep Gastroenterol. 2013 Mar 28;7(1):182-7. doi: 10.1159/000350673. Print 2013 Jan.

28.

Changes in plasma ghrelin and serum leptin levels after Cisplatin-based transcatheter arterial infusion chemotherapy for hepatocellular carcinoma.

Matsumura T, Arai M, Yoshikawa M, Sudo K, Nakamura K, Katsuno T, Kanai F, Yamaguchi T, Yokosuka O.

ISRN Gastroenterol. 2013;2013:415450. doi: 10.1155/2013/415450. Epub 2013 Mar 7.

29.

Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine.

Kamezaki H, Kanda T, Arai M, Wu S, Nakamoto S, Chiba T, Maruyama H, Fujiwara K, Kanai F, Imazeki F, Nomura F, Yokosuka O.

Int J Med Sci. 2013;10(5):567-74. doi: 10.7150/ijms.5795. Epub 2013 Mar 15.

30.

Simultaneous resection of disseminated hepatocellular carcinoma and colon cancer.

Haga Y, Chiba T, Ohira G, Kanai F, Yokota H, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Miyauchi H, Matubara H, Yokosuka O.

Case Rep Gastroenterol. 2013 Jan;7(1):37-43. doi: 10.1159/000346925. Epub 2013 Jan 23.

31.

Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation.

Maruyama H, Takahashi M, Shimada T, Sekimoto T, Kamesaki H, Kanai F, Yokosuka O.

AJR Am J Roentgenol. 2013 Mar;200(3):570-7. doi: 10.2214/AJR.12.8999.

PMID:
23436846
32.

Serum fibrinogen alpha C-chain 5.9 kDa fragment as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus.

Sogawa K, Noda K, Umemura H, Seimiya M, Kuga T, Tomonaga T, Nishimura M, Kanai F, Imazeki F, Takizawa H, Yoneda M, Nakajima A, Tsutsumi M, Yokosuka O, Nomura F.

Proteomics Clin Appl. 2013 Jun;7(5-6):424-31. doi: 10.1002/prca.201200094. Epub 2013 May 17.

PMID:
23382097
33.

Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma.

Ooka Y, Kanai F, Okabe S, Ueda T, Shimofusa R, Ogasawara S, Chiba T, Sato Y, Yoshikawa M, Yokosuka O.

Magn Reson Imaging. 2013 Jun;31(5):748-54. doi: 10.1016/j.mri.2012.10.028. Epub 2012 Dec 5.

PMID:
23218794
34.

Hepatic sarcoidosis with an increased serum level of immunoglobulin G4.

Inoue M, Chiba T, Zen Y, Yokota H, Kanda T, Ogasawara S, Sugiyama H, Arai M, Kanai F, Ogawa M, Imazeki F, Yokosuka O.

Intern Med. 2012;51(21):3095-8. Epub 2012 Nov 1.

35.

Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging.

Takahashi M, Maruyama H, Shimada T, Kamezaki H, Sekimoto T, Kanai F, Yokosuka O.

Eur J Radiol. 2013 Jan;82(1):75-84. doi: 10.1016/j.ejrad.2012.05.035. Epub 2012 Oct 29.

PMID:
23116806
36.

Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence?

Takahashi M, Maruyama H, Shimada T, Kamezaki H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O.

Ultrasound Med Biol. 2012 Nov;38(11):1902-10. doi: 10.1016/j.ultrasmedbio.2012.07.003.

PMID:
23026230
37.

Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors.

Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H, Omata M, Koike K.

Liver Int. 2012 Oct;32(9):1434-42. doi: 10.1111/j.1478-3231.2012.02838.x. Epub 2012 Jun 19.

38.

Aldehyde dehydrogenase 1 is associated with recurrence-free survival but not stem cell-like properties in hepatocellular carcinoma.

Suzuki E, Chiba T, Zen Y, Miyagi S, Tada M, Kanai F, Imazeki F, Miyazaki M, Iwama A, Yokosuka O.

Hepatol Res. 2012 Nov;42(11):1100-11. doi: 10.1111/j.1872-034X.2012.01028.x. Epub 2012 May 14.

PMID:
22583771
39.

Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules.

Maruyama H, Takahashi M, Sekimoto T, Kamesaki H, Shimada T, Kanai F, Yokosuka O.

Ultrasound Med Biol. 2012 Mar;38(3):383-8. doi: 10.1016/j.ultrasmedbio.2011.12.006. Epub 2012 Jan 20.

PMID:
22261511
40.

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, Ohta M, Tada M, Tanaka Y, Ikenoue T, Tateishi K, Isayama H, Kanai F, Fukushima N, Tada M, Kawabe T, Omata M, Koike K.

J Gastroenterol. 2012 Feb;47(2):203-13. doi: 10.1007/s00535-011-0482-y. Epub 2011 Nov 1.

PMID:
22041919
41.

Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K.

J Gastroenterol. 2012 Jan;47(1):71-8. doi: 10.1007/s00535-011-0462-2. Epub 2011 Sep 21.

PMID:
21935635
42.

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.

Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O.

Int J Cancer. 2012 Jun 1;130(11):2557-67. doi: 10.1002/ijc.26264. Epub 2011 Aug 20.

43.

Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.

Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, Koike K.

J Hepatol. 2011 Dec;55(6):1400-8. doi: 10.1016/j.jhep.2011.03.025. Epub 2011 May 19.

PMID:
21703185
44.

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.

Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, Toriyabe T, Shinozaki Y, Ooka Y, Mikata R, Chiba T, Okabe S, Imazeki F, Yoshikawa M, Yokosuka O.

Hepatol Int. 2011 Sep;5(3):850-6. doi: 10.1007/s12072-010-9249-4. Epub 2011 Jan 22.

PMID:
21484134
45.

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.

Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka T, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O.

J Viral Hepat. 2011 Jul;18(7):e292-7. doi: 10.1111/j.1365-2893.2010.01409.x. Epub 2010 Dec 3.

PMID:
21129130
46.

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M.

Cancer Chemother Pharmacol. 2011 Feb;67(2):315-24. doi: 10.1007/s00280-010-1320-2.

PMID:
20390419
47.

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.

Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, Yamamoto K, Yamamoto S, Kudo Y, Mohri D, Isomura Y, Ijichi H, Tateishi K, Kanai F, Ogawa S, Omata M, Koike K.

Biochem Biophys Res Commun. 2010 Apr 16;394(4):1042-6. doi: 10.1016/j.bbrc.2010.03.120. Epub 2010 Mar 21.

PMID:
20331976
48.

Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer.

Tada M, Kanai F, Tanaka Y, Sanada M, Nannya Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Imazeki F, Yoshida H, Ogawa S, Yokosuka O, Omata M.

Cancer Sci. 2010 May;101(5):1261-9. doi: 10.1111/j.1349-7006.2010.01500.x. Epub 2010 Jan 19.

49.

Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations.

Sugimoto T, Ohta M, Ikenoue T, Yamada A, Tada M, Fujishiro M, Ogura K, Yamaji Y, Okamoto M, Kanai F, Kawabe T, Omata M.

Int J Cancer. 2010 Oct 1;127(7):1562-9. doi: 10.1002/ijc.25180.

50.

Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3.

Asaoka Y, Kanai F, Ichimura T, Tateishi K, Tanaka Y, Ohta M, Seto M, Tada M, Ijichi H, Ikenoue T, Kawabe T, Isobe T, Yaffe MB, Omata M.

J Biol Chem. 2010 Feb 5;285(6):4185-94. doi: 10.1074/jbc.M109.038232. Epub 2009 Dec 7.

Supplemental Content

Support Center